Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

This study found that in women with PCOS, suppressive therapy using spironolactone plus oral contraceptives improved hirsutism more effectively than either treatment alone, with initial scores predicting success.

This study found that 5% topical minoxidil solution led to better hair regrowth response and quality in severe alopecia areata compared to 1% solution, despite regrowth often being cosmetically unacceptable.

This review discusses recent advances in the understanding of alopecia areata, focusing on immunity and genetics, and presents potential targets for therapy without reporting new clinical results.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This study indicates that individuals exposed to PPD mount varying immune responses, with either tolerance, subclinical inflammation, or allergy, suggesting no true non-responders to PPD.

This study found that a 15% topical minoxidil solution improved hair regrowth in 60% of women with female pattern hair loss who did not respond to the standard 5% solution, without adverse effects.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

PRP treatment helps 70.1% of hair loss patients after two sessions.

In this study, the authors identified the DHRS9 SNP rs72623193 as most significantly associated with response to dutasteride in treating male pattern hair loss, with additional variants potentially contributing.

Many patients with alopecia areata relapse after stopping tofacitinib.

This study found that IL-1 blockers are effective for SURF and identified predictors of colchicine resistance, emphasizing the need for refined diagnostic criteria and personalized treatment due to the heterogeneity observed within SURF.

This report describes a case of a woman with ophiasis-pattern alopecia areata who experienced significant hair regrowth and maintained it for 6 months after treatment with dupilumab, though she eventually relapsed.

In this retrospective study, 75% of patients with alopecia areata responded well to an 8-week oral methylprednisolone tapering treatment, but 28.4% relapsed within an average of 5.5 months; young age and extensive alopecia predicted poorer responses, and low vitamin D was linked to relapse.

This study found that a novel 15% topical minoxidil solution achieved a clinically significant hair regrowth response in 60% of women with female pattern hair loss who did not respond to 5% minoxidil, without increasing adverse events.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

In this study, 49% of patients with alopecia areata achieved a significant response to baricitinib, with a lower baseline severity, shorter disease duration, and longer treatment duration identified as significant predictors of treatment success.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

Eyebrow and eyelash regrowth usually matches scalp hair response in alopecia areata patients treated with baricitinib.

Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.

This review highlights that poor therapeutic responses in female pattern hair loss involve multiple factors, including pharmacogenetic influences and comorbidities. It suggests a framework to improve outcomes by identifying the primary contributors and using personalized treatment strategies.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

This study found that handheld dermoscopes with polarized light can be beneficial in assessing treatment success in alopecia areata by revealing changes in trichoscopic features like thinning hairs and short terminal hairs.

Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.

This review discusses the effects of protein-based cosmetics on hair properties and reports no new research findings, suggesting potential benefits for developing advanced, sustainable hair products.